Reviews |
From the Department of Internal Medicine, School of Medicine, Keio University, Tokyo, Japan
Correspondence to Koichi Hayashi, MD, PhD, Department of Internal Medicine, School of Medicine, Keio University, 35 Shinanomachi, Shinjuku-ku, Tokyo 160-8582, Japan. E-mail khayashi{at}sc.itc.keio.ac.jp
A large body of evidence has accrued indicating that voltage-gated Ca2+ channel subtypes, including L-, T-, N-, and P/Q-type, are present within renal vascular and tubular tissues, and the blockade of these Ca2+ channels produces diverse actions on renal microcirculation. Because nifedipine acts exclusively on L-type Ca2+ channels, the observation that nifedipine predominantly dilates afferent arterioles implicates intrarenal heterogeneity in the distribution of L-type Ca2+ channels and suggests that it potentially causes glomerular hypertension. In contrast, recently developed Ca2+ channel blockers (CCBs), including mibefradil and efonidipine, exert blocking action on L-type and T-type Ca2+ channels and elicit vasodilation of afferent and efferent arterioles, which suggests the presence of T-type Ca2+ channels in both arterioles and the distinct impact on intraglomerular pressure. Recently, aldosterone has been established as an aggravating factor in kidney disease, and T-type Ca2+ channels mediate aldosterone release as well as its effect on renal efferent arteriolar tone. Furthermore, T-type CCBs are reported to exert inhibitory action on inflammatory process and renin secretion. Similarly, N-type Ca2+ channels are present in nerve terminals, and the inhibition of neurotransmitter release by N-type CCBs (eg, cilnidipine) elicits dilation of afferent and efferent arterioles and reduces glomerular pressure. Collectively, the kidney is endowed with a variety of Ca2+ channel subtypes, and the inhibition of these channels by their specific CCBs leads to variable impact on renal microcirculation. Furthermore, multifaceted activity of CCBs on T- and N-type Ca2+ channels may offer additive benefits through nonhemodynamic mechanisms in the progression of chronic kidney disease.
Key Words: afferent arteriole efferent arteriole Ca2+ channel blockers renal microcirculation voltage-dependent Ca2+ channels renal disease efonidipine mibefradil
This article has been cited by other articles:
![]() |
L. Nordquist, R. Brown, A. Fasching, P. Persson, and F. Palm Proinsulin C-peptide reduces diabetes-induced glomerular hyperfiltration via efferent arteriole dilation and inhibition of tubular sodium reabsorption Am J Physiol Renal Physiol, November 1, 2009; 297(5): F1265 - F1272. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Fujimoto, M. Satoh, H. Nagasu, H. Horike, T. Sasaki, and N. Kashihara Azelnidipine exerts renoprotective effects by improvement of renal microcirculation in angiotensin II infusion rats Nephrol. Dial. Transplant., August 7, 2009; (2009) gfp407v1. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. L. Thai, G. C. Churchill, and W. J. Arendshorst NAADP receptors mediate calcium signaling stimulated by endothelin-1 and norepinephrine in renal afferent arterioles Am J Physiol Renal Physiol, August 1, 2009; 297(2): F510 - F516. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. J. Ball, D. P. Wilson, S. P. Turner, D. A. Saint, and J. F. Beltrame Heterogeneity of L- and T-Channels in the Vasculature: Rationale for the Efficacy of Combined L- and T-Blockade Hypertension, April 1, 2009; 53(4): 654 - 660. [Abstract] [Full Text] [PDF] |
||||
![]() |
W. Ge and J. Ren Combined L-/T-Type Calcium Channel Blockers: Ready for Prime Time Hypertension, April 1, 2009; 53(4): 592 - 594. [Full Text] [PDF] |
||||
![]() |
S. A. Davies and S. Terhzaz Organellar calcium signalling mechanisms in Drosophila epithelial function J. Exp. Biol., February 1, 2009; 212(3): 387 - 400. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. Perez-Reyes, A. L. Van Deusen, and I. Vitko Molecular Pharmacology of Human Cav3.2 T-Type Ca2+ Channels: Block by Antihypertensives, Antiarrhythmics, and Their Analogs J. Pharmacol. Exp. Ther., February 1, 2009; 328(2): 621 - 627. [Abstract] [Full Text] [PDF] |
||||
|
Circulation Research Home | Subscriptions | Archives | Feedback | Authors | Help | AHA Journals Home | Search Copyright © 2007 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited. |